dosing & administration
community-reported protocols, reconstitution, stacking, and cycling -- for educational purposes only
The Dosing Landscape
TB-500 runs on a two-phase model: a 4-6 week loading phase at mg doses twice weekly, then a reduced maintenance phase. The cadence tracks TB4's long tissue half-life -- plasma clears rapidly while tissue concentrations remain elevated for days, explaining why twice-weekly injections are the most widely reported community protocol.
Human PK is thin. Ruff 2010 tolerated IV TB4 up to 1,260 mg, but a Phase I trial says little about injury-repair dosing. Protocols below come from animal work and user reports.
Educational only, not medical advice. No regimen here is validated in human injury-healing trials.
Run the Dosing Numbers
pick a vial size and protocol; see reconstitution and weekly totals.
Why Twice-Weekly? The Half-Life Story
plasma clears in hours; tissue holds for days. step through the PK timeline.
loading phase vs maintenance phase
the two-phase protocol explained side by side.
loading phase
- duration: 4-6 weeks
- frequency: twice weekly
- community dose range: 2-5 mg per injection
- goal: saturate tissue compartments and establish a working concentration
- evidence basis: extrapolated from animal weight-based dosing -- no human data
maintenance phase
- duration: variable, often 4-8 weeks or as needed
- frequency: once weekly or less
- community dose range: 1-2 mg per injection
- goal: sustain tissue levels at a lower running cost
- evidence basis: purely community-derived; no clinical pharmacology supports this phase
key terms
pharmacokinetics — half-life
time for plasma concentration to drop by 50%. TB-500's plasma half-life is short (minutes to hours) but tissue concentrations remain elevated for days, explaining the twice-weekly injection schedule.
pharmacokinetics — reconstitution
dissolving a lyophilized (freeze-dried) peptide vial in bacteriostatic water to create an injectable solution. concentration depends on vial size and water volume added.
dosing protocol — loading phase
an initial higher-dose period (e.g. 2x/week for 4-6 weeks) intended to build up tissue levels before transitioning to maintenance dosing. not validated in human trials.
dosing protocol — maintenance phase
ongoing lower-dose injections (e.g. 2 mg every 1-2 weeks) used after a loading period to maintain the hypothesized therapeutic effect. entirely community-derived; no clinical basis.